Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 163

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 163
---
5% of net sales, as well as certain fees in the case of sublicenses or an “exit” event, all subject to the terms as described in the BIRAD License Agreement. We will also pay BIRAD different payments when reaching several milestones. 98 On March 19, 2024, we entered into a License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, which provides us with an exclusive, perpetual, worldwide and sublicensable license to use to Yissum’s patent titled “psychedelic compounds, methods of their preparation and uses thereof” to further develop, manufacture, and commercialize innovative compounds targeted at treating post traumatic stress disorder and other health conditions (the “Yissum PTSD License Agreement”) According to the Yissum PTSD License Agreement, we are required to pay Yissum annual maintenance fees ranging from $25,000 to $50,000 beginning of the fifth anniversary of the effective date of the Yissum PSTD License Agreement, and royalties at the rate of 3.0% of net sales, as well as certain fees in the case of sublicensing or an exit event, all subject to the terms as described in the Yissum PTSD License Agreement. We will also pay Yissum different payments when reaching several milestones. All right, title and interest in the patent (the Licensed Patent as defined in the Yissum PSTD License Agreement) vest solely in Yissum, and we shall hold and make use of the license granted. Subject to such Yissum’s ownership rights, all rights in results of our development shall be solely owned by us. On March 31, 2024 we entered into a License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, which provides us with an exclusive, perpetual, worldwide and sublicensable license to use Yissum’s patent “psychoactive compounds, methods of their preparation and uses thereof in the treatment of mental disorders” to further develop, manufacture, and commercialize innovative compounds targeted at Generation 3.0 psychedelic compounds for the treatment of mental disorders (the “Yissum Psychedelic License Agreement). According to the Yissum Psychedelic License Agreement, we are required to pay Yissum annual maintenance fees ranging from $25,000 to $50,000 beginning of the fifth anniversary of the effective date of the Yissum Psychedelic License Agreement, and we shall pay Yissum royalties at the rate of 3.0